Mejía-Guzmán J.E.,Metabolic-DysfunctionAssociated Steatotic Liver J.E. .2025 .Disease: Molecular Mechanisms, Clinical Implications and Emerging Therapeutic Strategies. International Journal of Molecular Sciences, 26 : .
Margini C.,Dufour J.F. .2016 .The Story of HCC in NAFLD: From Epidemiology, across Pathogenesis, to Prevention and Treatment. , 36 : 317-324.
Loomba R.,Sanyal A.J. .2013 .. The Global NAFLD Epidemic.” Nature Reviews Gastroenterology & Hepatology, 10 : 686-690.
Feng G. .2020 .Association between Ratio of γ-Glutamyl Transpeptidase to High-Density Lipoprotein Cholesterol and Prevalence of Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Cross-Sectional Study. ” Annals of Translational Medicine, 8 : .
Tilg H.,Moschen A.R. .2010 .Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis. ” Hepatology, 52 : 1836-1846.
Bołdys A. .2023 .Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. ” Medicina, 59 : .
Diehl A.M.,Day C. .2017 .. Pathogenesis and Treatment of Nonalcoholic Steatohepatitis.” New England Journal of Medicine, 377 : 2063-2072.
Khang A.R. .2019 .The Fatty Liver Index, a Simple and Useful Predictor of Metabolic Syndrome: Analysis of the Korea National Health and Nutrition Examination Survey 2010-. Metabolic Syndrome and Obesity: Targets and Therapy, : 181-190.
Fouda A. .2021 .A Randomized Controlled Trial Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxifylline on Egyptian Non-Alcoholic Steatohepatitis Patients.” European Review for Medical & Pharmacological Sciences. , 25 : .
Xing Y.,Diabetes Y. .2022 .Associations between GGT/HDL and MAFLD: A Cross-Sectional Study. Metabolic Syndrome and Obesity: Targets and Therapy, : 383-394.
Wang J. .2015 .ZJU Index: A Novel Model for Predicting Nonalcoholic Fatty Liver Disease in a Chinese Population. Scientific Reports, 5 : .
Li Q. .2022 .Gamma-Glutamyl Transferase to High-Density Lipoprotein Cholesterol Ratio Has a Non-Linear Association with Non-Alcoholic Fatty Liver Disease: A Secondary Prospective Cohort Study in Non-Obese Chinese Adults. , 9 : .
Cherubini A. .2024 .. Sexual Dimorphism of Metabolic Dysfunction-Associated Steatotic Liver Disease.” Trends in Molecular Medicine, : .
Jung H.S. .2019 .Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. American Journal of Gastroenterology, 114 : 453-463.
Ashraf S. . .An Open-Label Randomized Clinical Study to Compare the Effects of a Nutritional Supplement versus Vitamin E on Fibroscan Score in Nonalcoholic Steatohepatitis (NASH) Patients. Universal Journal of Public Health, 6(2018) : 56-62.
Saboori S. .2015 .Effect of Vitamin E Supplementation on Serum C-Reactive Protein Level: A Meta-Analysis of Randomized Controlled Trials. European Journal of Clinical Nutrition, 69 : 867-873.
Kumar R. .2020 .Association of High-Sensitivity C-Reactive Protein (hs-CRP) with Non-Alcoholic Fatty Liver Disease (NAFLD) in Asian Indians: A Cross-Sectional Study. ” Journal of Family Medicine and Primary Care, 9 : .
Debbabi M. .2016 .Protective Effects of α-Tocopherol, γ- Tocopherol and Oleic Acid, Three Compounds of Olive Oils and No Effect of Trolox, on 7-Ketocholesterol-Induced Mitochondrial and Peroxisomal Dysfunction in Microglial BV-2 Cells. International Journal of Molecular Sciences, 17 : .
Papatheodoridi M.,E. Cholongitas. M. .2018 .Diagnosis of NonAlcoholic Fatty Liver Disease (NAFLD): Current Concepts. ” Current Pharmaceutical Design, 24 : 4574-4586.
Derakhshandeh-Rishehri S.,Phospholipid-Vitamin E Complex S. .2020 .) on Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis of RCTs. Acta Endocrinologica (Bucharest), 16 : .
Hasegawa T. .2001 .Plasma Transforming Growth Factor-β1 Level and Efficacy of α-Tocopherol in Patients with NonAlcoholic Steatohepatitis: A Pilot Study. Alimentary Pharmacology & Therapeutics, 15 : 1667-1672.